ARANELLE
Clinical safety rating
cautionComprehensive clinical and safety monograph for ARANELLE (ARANELLE).
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
| Metabolism | Ethinyl estradiol is metabolized primarily by CYP3A4; norethindrone undergoes reduction and conjugation, with some involvement of CYP3A4. |
| Excretion | Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10% |
| Half-life | Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing |
| Protein binding | 97-98% bound to albumin and sex hormone-binding globulin (SHBG) |
| Volume of Distribution | 1.3-1.5 L/kg; moderate distribution into tissues including reproductive organs and liver |
| Bioavailability | Oral: approximately 85% (extensive first-pass metabolism; absolute bioavailability 85% based on IV reference) |
| Onset of Action | Oral: within 1-2 hours; peak effect 4-6 hours |
| Duration of Action | ~24 hours; therapeutic efficacy maintained throughout dosing interval |
| Molecular Weight | 312.45 |
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use caution. |
| Liver impairment | Contraindicated in patients with hepatic adenomas or active liver disease. Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to altered hormone metabolism. |
| Pediatric use | Safety and efficacy not established in pediatric patients before menarche. For post-menarchal adolescents, use same dosing as adults. |
| Geriatric use | Not indicated for use in postmenopausal women. No specific geriatric dosing. |
| 1st trimester | Contraindicated: known teratogenic effects (maskulinization of female fetus due to progestin activity). |
| 2nd trimester | Contraindicated: risk of fetal harm, including virilization of female genitalia. |
| 3rd trimester | Contraindicated: potential for adverse effects on fetal development. |
Clinical note
Comprehensive clinical and safety monograph for ARANELLE (ARANELLE).
| Placental transfer | Extensive placental transfer documented; progestins cross the placenta and can affect fetal development. |
| Breastfeeding | Excreted in breast milk; may cause adverse effects in nursing infants, including jaundice and breast enlargement. Use during breastfeeding not recommended. |
| Lactation Rating | L5 |
| Teratogenic Risk | Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects, particularly during first trimester. Use in second and third trimesters may cause fetal feminization (in males) and virilization (in females). |
| Fetal Monitoring | Monitor for signs of thromboembolism, hypertension, hepatotoxicity, and glucose intolerance. In pregnancy or suspected pregnancy, perform pregnancy test and discontinue immediately. |
| Fertility Effects | Reversible suppression of ovulation; normal fertility returns after discontinuation. No known permanent adverse effects on fertility. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives; risk increases with age and smoking intensity, especially in women over 35. Women should not smoke while using ARANELLE.
| Serious Effects |
Known or suspected pregnancyHistory of or current thromboembolic disordersKnown or suspected carcinoma of the breastUndiagnosed abnormal genital bleedingHepatic adenomas or carcinomasKnown hypersensitivity to any component
| Precautions | Thrombotic disorders (e.g., venous thromboembolism, stroke, MI), Cigarette smoking, Hypertension, Liver disease, Gallbladder disease, Glucose intolerance, Depression, Retinal thrombosis, Hereditary angioedema, Chloasma |
| Food/Dietary | No significant food interactions. Grapefruit juice has minimal effect on ethinyl estradiol pharmacokinetics; no restriction necessary. Avoid excessive alcohol consumption as it may increase liver strain. |
| Clinical Pearls | ARANELLE (ethinyl estradiol and drospirenone) is a combined oral contraceptive with an anti-mineralocorticoid effect due to drospirenone. Monitor potassium levels in patients with renal impairment or on medications that increase potassium. The 24/4 regimen with 30 mcg ethinyl estradiol and 3 mg drospirenone provides excellent cycle control. Consider in patients with acne or mild hirsutism due to drospirenone's anti-androgenic properties. Contraindicated in patients with migraines with aura, history of thromboembolic events, or liver disease. |
| Patient Advice | Take one tablet daily at the same time for 24 days of active pills followed by 4 placebo days. · Use backup contraception (e.g., condoms) for the first 7 days if starting for the first time. · Report any signs of blood clots (leg pain, chest pain, sudden shortness of breath, severe headache, vision changes) immediately. · Avoid smoking due to increased risk of cardiovascular side effects. · Inform your healthcare provider of all medications, especially those affecting potassium (e.g., ACE inhibitors, NSAIDs, potassium supplements). · If you miss a dose, follow the package instructions; if you miss more than one pill, use backup contraception. |
Loading safety data…